PTH - ETF AI Analysis
Top Page
Invesco DWA Healthcare Momentum ETF (PTH)
Rating:56Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the last few months, indicating solid recent momentum.
High-Performing Top Holdings
Many of the largest positions, including several biotech and healthcare names, have delivered strong year-to-date returns that support the fund’s overall performance.
Focused Healthcare Exposure
The fund is heavily concentrated in the health care sector, allowing investors to target a specific area of the market that has been performing well recently.
Negative Factors
Sector Concentration Risk
With almost all assets in health care, the ETF is vulnerable if this single sector experiences a downturn.
Limited Geographic Diversification
The fund invests almost entirely in U.S. companies, offering little protection if the U.S. market or healthcare industry faces challenges.
Relatively High Expense Ratio
The ETF’s fees are on the higher side for a passive fund, which can slightly reduce long-term returns compared with lower-cost alternatives.
PTH vs. SPDR S&P 500 ETF (SPY)
AUM263.69M
RegionNorth America
Expense Ratio0.60%
Beta0.95
IssuerInvesco
Inception DateOct 12, 2006
Dividend Yield2.51%
Asset ClassEquity
Index TrackedDorsey Wright Healthcare Tech Leaders TR
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume52,540
30 Day Avg. Volume51,517
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
73.33Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering55
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PTH Summary
PTH, the Invesco DWA Healthcare Momentum ETF, is a fund that follows the Dorsey Wright Healthcare Tech Leaders Index, focusing on U.S. healthcare companies showing strong recent performance. It holds a mix of biotech, drug makers, medical device firms, and healthcare service providers, including names like Guardant Health and Agilon Health. Someone might invest in PTH to seek growth from medical innovation and to get broad exposure to many healthcare stocks in a single investment. A key risk is that it is heavily concentrated in healthcare and momentum stocks, so its price can swing sharply and may fall if the sector or trend goes out of favor.
How much will it cost me?The Invesco DWA Healthcare Momentum ETF (Ticker: PTH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on momentum-driven strategies within the healthcare sector.
What would affect this ETF?The Invesco DWA Healthcare Momentum ETF (PTH) could benefit from ongoing advancements in healthcare technology, an aging population driving demand for medical services, and increased investment in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, pricing pressures in the healthcare industry, and potential economic downturns that could reduce consumer spending on healthcare. Its focus on U.S.-based healthcare companies and momentum-driven strategy makes it sensitive to market volatility and sector-specific trends.
PTH Top 10 Holdings
PTH is leaning hard into high-octane U.S. healthcare names, with biotech and innovative therapeutics setting the tone. Revolution Medicines and Liquidia are rising stars, helping power the fund thanks to strong momentum and upbeat pipeline narratives. 10x Genomics has also been climbing, adding a tech-flavored boost from the tools side of healthcare. On the softer side, Axsome Therapeutics and Guardant Health have seen more mixed, sometimes lagging action, reminding investors that momentum in this sector can shift quickly. Overall, it’s a concentrated bet on cutting-edge, domestically focused healthcare growth.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Revolution Medicines | 5.32% | $14.00M | $43.66B | 481.62% | 52 Neutral | |
| Roivant Sciences | 5.04% | $13.26M | $26.15B | 206.86% | 58 Neutral | |
| Guardant Health | 4.73% | $12.45M | $21.10B | 171.85% | 61 Neutral | |
| Axsome Therapeutics | 3.90% | $10.26M | $11.19B | 94.61% | 57 Neutral | |
| BrightSpring Health Services, Inc. | 3.88% | $10.22M | $12.21B | 161.50% | 67 Neutral | |
| Oruka Therapeutics | 3.05% | $8.02M | $7.35B | 638.75% | 41 Neutral | |
| Erasca | 2.82% | $7.43M | $6.43B | 1094.77% | 34 Underperform | |
| 10x Genomics | 2.66% | $6.99M | $7.31B | 330.83% | 60 Neutral | |
| Liquidia Technologies | 2.65% | $6.98M | $6.66B | 180.30% | 57 Neutral | |
| Replimune Group | 2.40% | $6.32M | $1.26B | 174.48% | 42 Neutral |
PTH Technical Analysis
Positive
―
Price Trends
58.02
Positive
54.49
Positive
51.80
Positive
Market Momentum
1.02
Negative
68.21
Neutral
85.72
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PTH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 59.66, equal to the 50-day MA of 58.02, and equal to the 200-day MA of 51.80, indicating a bullish trend. The MACD of 1.02 indicates Negative momentum. The RSI at 68.21 is Neutral, neither overbought nor oversold. The STOCH value of 85.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTH.
PTH Peer Comparison
Comparison Results
Performance Comparison
PTH
Invesco DWA Healthcare Momentum ETF
64.07
26.08
68.65%
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PSCH
Invesco S&P SmallCap Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents